Avalo shareholders approve equity plan increase to 3.55M shares, ESPP, and elect directors

Avalo Therapeutics, Inc.

Stockholders approved Fourth Amended and Restated 2016 Equity Incentive Plan, increasing share reserve to 3,548,882 shares with automatic annual increases through 2034.
Stockholders also approved Amended and Restated Employee Stock Purchase Plan, reserving 234,878 shares with automatic annual increases through 2034.
All seven director nominees were elected: June Almenoff, Mitchell Chan, Jonathan Goldman, Aaron Kantoff, Gilla Kaplan, Garry Neil, Samantha Truex.
Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.
Proposal to approve issuance of shares for Series C Preferred conversion, warrant exercise, and AlmataBio milestone obligations was approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.